Aspirin use for primary cardiovascular prevention has dropped more than 50% since 2018, tracking revised clinical guidelines.
Key Takeaways
The decline aligns with major 2018-2019 guideline revisions from ACC/AHA and USPSTF, which downgraded aspirin recommendations for primary prevention after large trials showed net harm from bleeding.
“Primary prevention” means patients with no prior cardiovascular event – the population where benefit-risk calculus shifted most sharply.
The >50% reduction is a substantial population-level behavior change, suggesting physician prescribing and patient habits both responded to updated evidence.
Secondary prevention (post-heart attack, post-stroke) was not implicated – the shift is specific to healthy adults taking aspirin prophylactically.
Hacker News Comment Review
The single comment frames this as a positive example of evidence-based medicine working as intended: guidelines updated, practice followed. That framing is optimistic but worth noting given how rare clean pivots are in clinical culture.
No substantive technical or mechanistic discussion yet – the comment does not address the underlying trials (ASPREE, ARRIVE, ASCEND), lag time in practice change, or whether the drop is uniform across demographics and geographies.
Notable Comments
@Herodotus38: “concrete evidence that physicians made changes when the evidence showed a change was needed.”
